Kolevzon, A. http://orcid.org/0000-0001-8129-2671
Breen, M. S. http://orcid.org/0000-0002-6739-939X
Siper, P. M. http://orcid.org/0000-0002-9659-8232
Halpern, D. http://orcid.org/0000-0001-6745-1197
Frank, Y. http://orcid.org/0000-0003-0979-1032
Rieger, H.
Weismann, J.
Trelles, M. P. http://orcid.org/0000-0002-7442-3677
Lerman, B. http://orcid.org/0000-0002-9032-1224
Rapaport, R. http://orcid.org/0000-0002-0915-3551
Buxbaum, J. D. http://orcid.org/0000-0001-8898-8313
Funding for this research was provided by:
National Institute of Mental Health (R34 MH100276)
Article History
Received: 12 November 2021
Accepted: 1 March 2022
First Online: 8 April 2022
Declarations
:
: The protocol was approved by the Mount Sinai Program for the Protection of Human Subjects and all caregivers signed informed consent.
: Not applicable.
: AK receives research support from AMO Pharma and consults to Acadia, Alkermes, Ritrova, Jaguar, Neuren, GW Pharma, and Ovid Therapeutics. JDB has a shared patent with Mount Sinai for IGF-1 in Phelan-McDermid syndrome. No other authors have competing interests to disclose.